Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)

Market Cap	46.38B
Revenue (ttm)	3.86B
Net Income (ttm)	350.11M
Shares Out	1.11B
EPS (ttm)	0.31
PE Ratio	135.40
Forward PE	82.52
Dividend	0.42 (0.98%)
Ex-Dividend Date	May 15, 2025

Volume	3,700,900
Average Volume	4,970,568
Open	41.58
Previous Close	41.81
Day's Range	41.50 - 42.88
52-Week Range	25.48 - 47.50
Beta	-0.02
RSI	49.78
Earnings Date	Aug 15, 2025

About SHE:002653

Haisco Pharmaceutical Group Co., Ltd. research, develops, manufactures, and sells pharmaceuticals in China. The company offers cycloporol, dolasetron mesylate, polyene phosphatidylcholine, compound amino acid, and methylprednisolone sodium injections, as well as flupenthixol melitracen tablets. It offers its products in various therapeutic fields, including anesthesia, parenteral nutrition, tumor antiemetic, liver, gallbladder digestion, antibiotics, cardiovascular, and cerebrovascular. The company was formerly known as Xizang Haisco Pharmaceut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 5,337
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002653

Financial Performance

In 2024, SHE:002653's revenue was 3.72 billion, an increase of 10.92% compared to the previous year's 3.36 billion. Earnings were 395.46 million, an increase of 34.00%.